| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.2M | 0.00% | 603.80K | −18% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ALXO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 16, 2026 | Lettmann JasonChief Executive Officer | Sale at price 1.93 per share. | 2.2K | $4.30K |
| Aug 16, 2026 | Wong ShellyOfficer | Sale at price 1.93 per share. | 573 | $1.11K |
| Jun 30, 2026 | Wong ShellyOfficer | Sale at price 2.04 per share. | 1.4K | $2.86K |
| Mar 18, 2026 | Lettmann JasonChief Executive Officer | Sale at price 2.17 per share. | 12.3K | $26.71K |
| Mar 18, 2026 | Pinto ShellyOfficer | Sale at price 2.17 per share. | 903 | $1.96K |
| Feb 17, 2026 | Pinto ShellyOfficer | Sale at price 2.27 per share. | 565 | $1.28K |
| Feb 1, 2026 | Goodman Corey SDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.57 per share. | 3.18M | $5.00M |
| Jan 5, 2026 | Pinto ShellyOfficer | Sale at price 1.11 per share. | 3.9K | $4.36K |
| Sep 16, 2025 | Lettmann JasonChief Executive Officer | Purchase at price 1.07 - 1.08 per share. | 92.2K | $99.35K |
| Aug 17, 2025 | Shantharam HarishChief Financial Officer | Purchase at price 0.78 per share. | 75K | $58.40K |
| Aug 14, 2025 | Lettmann JasonChief Executive Officer | Sale at price 0.64 per share. | 2.4K | $1.52K |
| Aug 14, 2025 | Pinto ShellyOfficer | Sale at price 0.64 per share. | 611 | $391 |
| Jul 6, 2025 | Pinto ShellyOfficer | Sale at price 0.45 per share. | 2K | $905 |
| Jun 29, 2025 | Pinto ShellyOfficer | Sale at price 0.43 per share. | 1.5K | $659 |
| Mar 13, 2025 | Lettmann JasonChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 42K | — |
| Mar 13, 2025 | Pinto ShellyOfficer | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Feb 18, 2025 | Lettmann JasonChief Executive Officer | Sale at price 1.15 per share. | 2.2K | $2.48K |
| Feb 18, 2025 | Pons JaumePresident | Sale at price 1.15 per share. | 1.3K | $1.52K |
| Feb 18, 2025 | Pinto ShellyOfficer | Sale at price 1.15 per share. | 550 | $633 |
| Jan 5, 2025 | Pinto ShellyChief Financial Officer | Sale at price 1.80 per share. | 2.2K | $4.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 54.0 | 21.3 | -5.0 | -15.2 | 11.8 | 8.9 | -6.3 | -0.5 | -28.0 | -29.5 | −13.3% | ||
| 2025 | -12.6 | -24.7 | -43.4 | -13.3 | -10.0 | -14.6 | 36.9 | 106.0 | 56.4 | -15.8 | -11.0 | -17.5 | −32.3% |
| 2024 | -3.2 | 1.8 | -24.0 | 52.6 | -37.5 | -43.3 | -20.4 | -51.7 | -21.6 | -21.4 | 3.5 | 12.8 | −88.8% |
| 2023 | -17.5 | -28.8 | -31.7 | 31.4 | 12.3 | 12.6 | -18.6 | -30.3 | 12.7 | 50.0 | 8.9 | 89.9 | +32.1% |
| 2022 | -25.5 | 13.3 | -6.7 | -24.4 | -40.0 | 5.5 | 19.7 | 34.3 | -26.4 | 26.9 | -8.6 | 1.5 | −47.6% |
| 2021 | -8.1 | 1.3 | -8.2 | -15.0 | -9.7 | -3.3 | 7.1 | 19.5 | 5.5 | -24.1 | -42.6 | -33.2 | −75.1% |
| 2020 | 23.7 | -6.7 | 4.7 | 94.7 | 12.0 | +163.6% |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Buy / hold / sell counts